EGFR and glioblastoma: The EGFR alterations found to be associated with TAT-Cx43266–283 effect in this study, such as EGFR amplification and EGFRvIII variant, are among the most common oncogenic2,4 and molecular hallmarks of GBM.42 Therefore, TAT-Cx43266–283 could potentially be beneficial to numerous GBM patients.